NEUMORA THERAPEUTICS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 31 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-08-21: Reporting owner Aurora Daljit Singh; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-21: Reporting owner Aurora Daljit Singh; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-20: Reporting owner Aurora Daljit Singh; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-20: Reporting owner Aurora Daljit Singh; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
NMRA insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-08-21 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,553 88,974 owned after | $0.72 exercise price | $1.63 | 2026-08-21 |
| 2026-08-21 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,055 94,798 owned after | $0.72 exercise price | $1.63 | 2026-08-21 |
| 2026-08-20 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −67,741 109,527 owned after | $0.72 exercise price | $1.52 | 2026-08-21 |
| 2026-08-20 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −45,026 0 owned after | $0.72 exercise price | $1.52 | 2026-08-21 |
| 2026-08-20 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,685 115,853 owned after | $0.72 exercise price | $1.52 | 2026-08-21 |
| 2026-08-20 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $1.52 exercise price | $1.52 | 2026-08-21 |
| 2026-08-20 | BERNS PAUL L Director, Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +500,000 500,000 owned after | $1.52 exercise price | $1.52 | 2026-08-21 |
| 2026-08-20 | Duncan Jason Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +375,000 375,000 owned after | $1.52 exercise price | $1.52 | 2026-08-21 |
| 2026-08-20 | Milligan Michael Lee Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +175,000 175,000 owned after | $1.52 exercise price | $1.52 | 2026-08-21 |
| 2026-08-20 | Pinto Joshua Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +500,000 500,000 owned after | $1.52 exercise price | $1.52 | 2026-08-21 |
| 2026-08-19 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,268 23,367 owned after | $0.72 exercise price | $1.64 | 2026-08-19 |
| 2026-08-19 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,732 177,268 owned after | $0.72 exercise price | $1.64 | 2026-08-19 |
| 2026-08-19 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −30,918 45,026 owned after | $0.72 exercise price | $1.64 | 2026-08-19 |
| 2026-08-18 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −34,162 36,635 owned after | $0.72 exercise price | $1.64 | 2026-08-19 |
| 2026-08-18 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −34,987 75,944 owned after | $0.72 exercise price | $1.64 | 2026-08-19 |
| 2026-08-17 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,890 0 owned after | $0.72 exercise price | $1.52 | 2026-08-19 |
| 2026-08-17 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,355 192,546 owned after | $0.72 exercise price | $1.52 | 2026-08-19 |
| 2026-08-17 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,424 70,797 owned after | $0.72 exercise price | $1.52 | 2026-08-19 |
| 2026-08-17 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1 999,999 owned after | $0.72 exercise price | $1.52 | 2026-08-19 |
| 2026-08-17 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,279 110,931 owned after | $0.72 exercise price | $1.52 | 2026-08-19 |
| 2026-08-17 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −29,737 0 owned after | $0.72 exercise price | $1.52 | 2026-08-19 |
| 2026-05-27 | Burow Kristina Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $1.86 exercise price | $1.86 | 2026-05-29 |
| 2026-05-27 | Fust Matthew K Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $1.86 exercise price | $1.86 | 2026-05-29 |
| 2026-05-27 | Piacquad David Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $1.86 exercise price | $1.86 | 2026-05-29 |
| 2026-05-27 | Halawa Alaa Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $1.86 exercise price | $1.86 | 2026-05-29 |
| 2026-05-27 | Ho Maykin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $1.86 exercise price | $1.86 | 2026-05-29 |
| 2026-01-08 | Milligan Michael Lee Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +350,000 350,000 owned after | $2.33 exercise price | $2.33 | 2026-01-09 |
| 2026-01-08 | Aurora Daljit Singh Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +750,000 750,000 owned after | $2.33 exercise price | $2.33 | 2026-01-09 |
| 2026-01-08 | Duncan Jason Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +750,000 750,000 owned after | $2.33 exercise price | $2.33 | 2026-01-09 |
| 2026-01-08 | Pinto Joshua Officer (President) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,200,000 1,200,000 owned after | $2.33 exercise price | $2.33 | 2026-01-09 |
| 2026-01-08 | BERNS PAUL L Director, Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,650,000 1,650,000 owned after | $2.33 exercise price | $2.33 | 2026-01-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |